[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoma-large-b-cell-diffuse\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoma-large-b-cell-diffuse":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,40,64,75,106,131,164,189,214,245,272],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100053501","phase-2-a-clinical-study-of-zilovertamab-vedotin-mk-2140-plus-rituximab-plus-cyclophosphamide-doxorubicin-and-prednisone-r-chp-versus-polatuzumab-vedotin-plus-r-chp-in-people-with-diffuse-large-b-cell-lymphoma-dlbcl-mk-2140-011waveline-011-100053501",false,"NCT06890884","A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011\u002FwaveLINE-011)","A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has histologically confirmed diagnosis of germinal center B-cell (GCB) subtype of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, according to the World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues.\n* Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale.\n* Has received no prior treatment for their DLBCL.\n* Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART).\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization.\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history of transformation of indolent disease to DLBCL.\n* Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma.\n* Has Ann Arbor Stage I DLBCL.\n* Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident\u002Fstroke (\\\u003C6 months prior to enrollment), myocardial infarction (\\\u003C6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication.\n* Has clinically significant pericardial or pleural effusion.\n* Has ongoing Grade \\>1 peripheral neuropathy.\n* Has a demyelinating form of Charcot-Marie-Tooth disease.\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.\n* Has ongoing corticosteroid therapy.\n* Known additional malignancy that is progressing or has required active treatment within the past 2 years.\n* Known active central nervous system (CNS) lymphoma.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years.\n* Has active infection requiring systemic therapy.\n* Has active HBV (defined as HBsAg positive and detectable HBV deoxyribonucleic acid (DNA)) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection.\n* Has history of stem cell\u002Fsolid organ transplant.","ALL","18 Years",{"count":19,"type":20},594,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing.\n\nThe goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.",[26],"Lymphoma, Large B-Cell, Diffuse","RECRUITING","2026-07-10",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2025-04-11",{"date":35,"type":20},"2032-12-16",{"name":37,"class":38},"Merck Sharp & Dohme LLC","INDUSTRY",136,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100632906","phase-1-a-clinical-study-of-mk-1045-in-people-with-non-hodgkin-lymphoma-mk-1045-008-100632906","NCT07519772","A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","A Phase 1b\u002F2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has disease that has relapsed (disease progression after remission) or is refractory (failure to achieve complete or partial response) to at least 2 prior systemic lines of therapy.\n* Has a histologically confirmed diagnosis of follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).\n* DLBCL participants only: has progressed after or is ineligible for transplant and chimeric antigen receptor T (cell) (CAR-T) therapy.\n* Has provided tumor tissue sample (archival or newly obtained, if performed per standard of care).\n* Has documented retained expression of cluster of differentiation 19 (CD19) in tumor tissue obtained by biopsy after disease progression on CD19-targeting therapy, if experienced disease progression after prior CD19-targeting therapy.\n* Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy if has a history of HIV infection.\n* Has undetectable hepatitis B virus (HBV) viral load and received and will continue to receive HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive.\n* Has undetectable hepatitis C virus (HCV) viral load and received HCV antiviral therapy if has a history of HCV infection.\n* Has radiographically measurable disease per Lugano Response Criteria.\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has received a solid organ transplant.\n* Had or has clinically relevant central nervous system (CNS) diseases.\n* Has a history of serious cardiovascular or cerebrovascular diseases.\n* Had prior allogenic stem cell transplantation with acute graft-versus-host-disease (GVHD); has ongoing evidence of chronic GVHD manifesting as skin involvement, diarrhea, or increased serum bilirubin; or requires systemic immunosuppression for GVHD.\n* Is HIV-infected with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.\n* Has received a live or live-attenuated vaccine within 30 days of randomization.\n* Has received prior CAR-T therapy within 3 months before the first dose of the study intervention.\n* Has a known additional malignancy that is progressing or required active treatment within the past 2 years.\n* Has known active CNS lymphoma or involvement.\n* Has active autoimmune disease that required systemic treatment in the past 2 years.\n* Has active infection requiring systemic therapy.\n* Has a history of severe bleeding disorders.\n* Has not recovered from major surgery or has ongoing surgical complications.\n* Has diagnosis of primary mediastinal B-cell lymphoma.",{"count":48,"type":20},200,[50,23],"PHASE1","Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system.\n\nIn this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer.\n\nThe goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.",[53,54,26],"Lymphoma, Non-Hodgkin","Lymphoma, Follicular","2026-07-01",{"date":57,"type":31},"2026-07-02",{"date":59,"type":31},"2026-05-03",{"date":61,"type":20},"2031-04-01",{"name":37,"class":38},13,{"id":65,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":67,"briefSummary":24,"conditions":68,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":73,"locationsCount":74},"100584556",{"count":19,"type":20},[23],[26],"2026-06-30",{"date":57,"type":31},{"date":33,"type":31},{"date":35,"type":20},{"name":37,"class":38},133,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100600733","phase-1-a-study-of-ly4152199-in-participants-with-previously-treated-b-cell-malignancies-baffrontier-1--100600733","NCT07101328","A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )","BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies","BAF_FRontier-1","Inclusion Criteria:\n\n* Must have a diagnosis of either follicular lymphoma or diffuse large B-cell lymphoma.\n* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Estimated life expectancy of greater than or equal to (≥)12 weeks as judged by the Investigator.\n* Participants with select tumor types must have measurable or assessable disease as defined below:\n\n  * Participants with lymphoma must have at least 1 bi-dimensionally measurable lesion or in the absence of measurable lymphadenopathy, documentation of bone marrow involvement.\n  * Participants with Waldenstrom macroglobulinemia (WM) must have measurable disease, defined as the presence of serum IgM with a minimum IgM level of greater than (\\>)2 times (×) upper limit of normal (ULN) based on local laboratory testing.\n* Must be able to comply with inpatient\u002Foutpatient treatment, laboratory monitoring, and required clinic visits for the duration of trial participation.\n* Must have adequate organ function.\n\nPhase 1 Dose Escalation (Cohort A) Participants - Must have histologically confirmed relapsed\u002Frefractory B-cell malignancy.\n\nPhase 1 Dose Optimization (Cohort B) Participants\n\n\\- Must have histologically confirmed relapsed\u002Frefractory diffuse large B-cell lymphoma (DLBCL) de novo or transformed from follicular lymphoma (FL).\n\nExclusion Criteria:\n\nAll Participants\n\n* Known or suspected peripheral blood involvement by malignant cells with an absolute lymphocyte count of greater than or equal to (≥) 5000 cells per microliter (μL).\n* Known or suspected central nervous system (CNS) involvement by systemic lymphoma.\n* Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n* Any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 2 at the time of starting trial treatment except for alopecia.\n* Autologous stem cell transplantation within 100 days of this study for post autologous transplant individuals.\n* Residual symptoms of neurotoxicity or cytopenias from prior chimeric antigen receptor T-cell therapy (CAR-T) or bispecifics. Exception: Cytopenia related to prior CAR-T or bispecifics allowed if they meet the adequate organ function criteria.\n* Known or suspected history of macrophage activation syndrome or hemophagocytic lymphohistiocytosis (HLH).\n* Active second malignancies, unless in remission, with life expectancy greater than 2 years with Sponsor approval.\n* History of autoimmune disease\n* Significant cardiovascular disease\n* Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection (except for fungal nail infection), or other clinically significant active disease process\n* Vaccination with a live vaccine within 4 weeks prior to signing informed consent form (ICF).\n* Have current or had a history of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins).\n* Prior treatment with B-cell activating factor receptor (BAFF-R) directed therapies (e.g., monoclonal antibody, CAR-T or bispecific antibody).\n* Pregnant and\u002For planning to breastfeed during the trial or within 90 days of the last dose of study intervention.\n* Known hypersensitivity to any component or excipient of LY4152199.",{"count":84,"type":20},215,[50],"The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.",[53,88,26,54,89,90,91],"B-cell Lymphoma","Lymphoma, B-cell Marginal Zone","Waldenstrom Macroglobulinemia","Lymphoma, Mantle Cell",[93,94],"B- cell activating factor receptor (BAFFR)","Bispecific antibody","NOT_YET_RECRUITING","2026-06-19",{"date":98,"type":31},"2026-06-23",{"date":100,"type":20},"2026-06",{"date":102,"type":20},"2029-09",{"name":104,"class":38},"Eli Lilly and Company",50,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100471652","phase-1-a-study-of-jnj-90014496-in-participants-with-b-cell-non-hodgkin-lymphoma-100471652","NCT05421663","A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","A Phase 1b\u002F2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19\u002FCD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Participant must be greater than or equal to (\\>=) 18 years of age, at the time of signing informed consent\n* Tumor must be histologically confirmed cluster of differentiation (CD)19 and\u002For CD20 positive\n* Must meet the indications for each subtype in Phase 1b as specified in protocol and Phase 2 participants must have following: Diagnosis of Large B-cell lymphoma (LBCL), Follicular large B-cell lymphoma (FLBCL), or transformation of indolent lymphoma; Received at least 2 prior lines of systemic therapy; Relapsed or refractory disease defined as 1 or more of the following: Stable disease or Progressive disease (PD) as best response to most recent anti-lymphoma therapy OR disease progression or recurrence after a partial response (PR) or complete response (CR) to most recent anti lymphoma therapy; cohort specific requirements as mentioned in protocol\n* Measurable disease as defined by Lugano 2014 classification\n* Eastern cooperative oncology group (ECOG) performance status of 0 to 2\n\nExclusion Criteria:\n\n* History of symptomatic deep vein thrombosis or pulmonary embolism within six months of apheresis (line associated deep vein thrombosis is allowed)\n* History of stroke, unstable angina, myocardial infarction, congestive heart failure New York Heart Association (NYHA) Class III or IV, severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of apheresis\n* History of a seizure disorder, dementia, cerebellar disease or neurodegenerative disorder\n* Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system\n* Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)\n* Evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection\n* Diagnosis of Human herpes virus (HHV) 8-positive DLBCL or T cell\u002Fhistiocyte-rich large B-cell lymphoma or Burkitt and high-grade B-cell lymphoma with 11q aberrations (previously Burkitt-like lymphoma) or Richter's transformation or Lymphomatoid granulomatosis or Plasmablastic lymphoma or Waldenstrom's Macroglobulinemia\n* Any prior solid organ or allogeneic stem cell transplantation\n* Autologous stem cell transplant within 12 weeks of apheresis; Prior CAR-T cell therapy within 12 weeks of apheresis",{"count":114,"type":20},439,[50,23],"This is a Phase 1b\u002F2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r\u002Fr) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).",[53,118,26],"Lymphoma, B-Cell",[120],"CD20\u002FCD19","2026-06-04",{"date":123,"type":31},"2026-06-05",{"date":125,"type":31},"2022-08-12",{"date":127,"type":20},"2041-07-30",{"name":129,"class":38},"Janssen Research & Development, LLC",32,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":150,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":163},"100581617","phase-2-cd70-targeted-immunopet-imaging-of-malignant-cancers-100581617","NCT06852638","CD70-targeted immunoPET Imaging of Malignant Cancers","CD70-targeted PET\u002F CT in the Diagnosis of Malignant Cancers","Inclusion Criteria:\n\n* Aged 18-80 year-old and of either sex；\n* Histologically confirmed diagnosis of renal cancer (especially ccRCC)\u002Flymphoma\u002FNPC or suspected renal cancer\u002Flymphoma\u002FNPC by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.","80 Years",{"count":140,"type":20},300,[23],"This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.",[144,145,146,26,147,148,149],"Renal Cancer","Renal Clear Cell Carcinoma","Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma","Nasopharyngeal Carcinoma",[151,152,144,146,149],"The cluster of differentiation (CD70)","ImmunoPET","2026-05-07",{"date":155,"type":31},"2026-05-12",{"date":157,"type":31},"2024-12-23",{"date":159,"type":20},"2026-12-23",{"name":161,"class":162},"RenJi Hospital","OTHER",1,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":172,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100500754","phase-2-a-phase-ii-study-of-glofitamab-plus-polatuzumab-r-chp-for-patients-with-high-risk-diffuse-large-b-cell-lymphoma-100500754","NCT05800366","A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","Inclusion Criteria:\n\n* Previously untreated patients with CD20-positive DLBCL, including one of the following diagnoses by 2016 WHO classification of lymphoid neoplasms\n\n  * DLBCL, not otherwise specified (NOS)\n  * T-cell\u002Fhistiocyte-rich large B-cell lymphoma\n  * Epstein-Barr virus-positive DLBCL, NOS\n  * ALK-positive large B-cell lymphoma\n  * HHV8-positive DLBCL, NOS\n  * High-grade B-cell lymphoma (HGBCL), NOS\n  * HGBCL with translocations of MYC and BCL-2, or MYC and BCL-6\n* Availability of archival (within 90 days) or freshly collected tumor tissue before study enrollment. If archival tissue is unavailable or is determined to be inadequate, tumor tissue must be obtained from a biopsy performed at screening, unless an exception is given after consultation with the principal investigator.\n* IPI score of 2-5\n* ECOG Performance Status of 0, 1, or 2 (see Appendix A)\n* Greater than or equal to 18 years at the time of signing informed consent\n* Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)\n* Adequate hematologic function (unless due to underlying disease, as established for example, by extensive bone marrow involvement or due to hypersplenism secondary to the involvement of the spleen by DLBCL per the investigator), defined as follows:\n\n  * Hemoglobin ≥ 9.0 g\u002FdL without transfusion for 14 days before first treatment\n  * ANC ≥ 1,000\u002FμL\n  * Platelet count ≥ 75,000\u002FμL\n* Participants must have adequate organ as defined below:\n\n  * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) or \\\u003C 3 x ULN in participants with Gilbert's disease\n  * PT or INR \\> 1.5 the ULN in the absence of therapeutic anticoagulation or lupus anticoagulant\n  * AST(SGOT)\u002FALT(SGPT) ≤ 2.5 × institutional ULN\n  * Adequate renal function defined by serum creatinine ≤1.5 x ULN or creatinine clearance (by Cockcroft-Gault) ≥ 40 ml\u002Fmin\n* At least one bi-dimensionally FDG-avid measurable lymphoma lesion on PET\u002FCT scan, defined as \\> 1.5 cm in its longest dimension on CT scan\n* Women of childbearing potential (WOCBP) must agree to use effective contraception when sexually active. Women must remain abstinent or use methods of contraception, including at least one method with a failure rate of \\\u003C1% per year, during the treatment period and for 12 months after the final dose of pola-R-CHP, 2 months after the last dose of glofitamab, and 9 months after the last dose of polatuzumab whichever is longer. Examples of contraceptive methods with a failure rate of \\\u003C1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control. The use of condoms by male patients is required unless the female partner is permanently sterile.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 12 months after the final dose of pola-R-CHP, 2 months after the last dose of glofitamab, and 9 months after the last dose of polatuzumab whichever is longer. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Male patients considering preservation of fertility should bank sperm before study treatment.\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients must be willing to have monthly testing and antiviral therapy if indicated. Participants with a history of hepatitis C virus (HCV) infection must have undetectable viral load.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Contraindication to any of the individual components of study drugs, including prior receipt of anthracyclines, or history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, or known sensitivity or allergy to murine products. Patients with a history of hypersensitivity to dexamethasone or systemic corticosteroids will also be excluded\n* Prior organ transplantation\n* History of indolent lymphoma or current diagnosis of the following: follicular lymphoma grade 3B; B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma (grey-zone lymphoma); primary mediastinal (thymic) large B-cell lymphoma; Burkitt lymphoma; CNS lymphoma (primary or secondary involvement), primary effusion DLBCL, and primary cutaneous DLBCL\n* Prior therapy for DLBCL with the exception of:\n\n  * Palliative, short-term treatment with corticosteroids (up to 7 days).\n  * One cycle of R-CHOP\n* Prior radiotherapy to the mediastinal\u002Fpericardial region\n* Prior treatment with cytotoxic drugs within 5 years of screening for any condition (e.g., cancer, rheumatoid arthritis) or prior use of any anti-CD20 antibody\n* Prior use of any monoclonal antibody within 3 months of the start of Cycle 1; any investigational therapy within 28 days prior to the start of Cycle 1; vaccination with live vaccines within 28 days prior the start of Cycle 1\n* Corticosteroid use \\> 30 mg\u002Fday of prednisone or equivalent, for purposes other than lymphoma symptom control. Patients receiving corticosteroid treatment with ≤ 30 mg\u002Fday of prednisone or equivalent for reasons other than lymphoma symptom control must be documented to be on a stable dose of at least 4 weeks' duration prior to the start of Cycle 1. Patients who require lymphoma symptom control during screening may receive steroids in the following manner: Up to 30 mg\u002Fday of prednisone or equivalent may be used for lymphoma symptom control during screening, including prior to finalization of staging (not included as part of pre-phase treatment). If glucocorticoid treatment is urgently required at higher doses for lymphoma symptom control prior to the start of study treatment, tumor assessments must be completed prior to initiation of \\> 30 - 100 mg\u002Fday of prednisone or equivalent. Prednisone \\> 30 - 100 mg\u002Fday or equivalent may be given for a maximum of 7 days as a pre-phase treatment. As part of the pre-phase treatment.\n* History of other malignancies, except:\n\n  * Malignancy treated medically or surgically with curative intent and with no known active disease present for ≥2 years before the first dose of study drug\n  * Adequately treated skin cancer or lentigo maligna without evidence of disease\n  * Adequately treated carcinoma in situ without evidence of disease.\n  * Localized prostate cancer and low-risk prostate cancer on active surveillance (Gleason score 6 or below, stage 1 or 2)\n  * In the opinion of the treating investigator, there is limited potential to interfere with the safety or efficacy of the investigational regimen. Such exceptions must be approved by the principal investigator.\n* Lactating or pregnant. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before the start of treatment, and a negative result must be documented\n* Known active infection, or reactivation of a latent infection, whether bacterial, viral; or any major episode of infection requiring hospitalization or treatment with IV antibiotics (for IV antibiotics, this pertains to completion of last course of antibiotic treatment) within 2 weeks of dosing\n* Known history of HIV or HTLV-1 seropositive status. HTLV-1 testing is required for patients from endemic countries (Japan and Melanesia and countries in the Caribbean basin, South America, Central America, and sub-Saharan Africa)\n* Clinically significant liver disease including active viral hepatitis infection, cirrhosis, or current alcohol abuse\n* Evidence of significant or uncontrolled concomitant diseases that could affect compliance to the protocol or interpretation of the results including significant or extensive history of cardiovascular disease such as New York Heart Association Class III or IV or objective Class C or D cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina, or pulmonary disease\n* Known history of central nervous system or neurologic disease including stroke or intracranial hemorrhage within 3 months prior to enrollment or seizure disorder\n* Grade 2 or greater peripheral neuropathy at baseline or demyelinating form of Charcot-Marie-Tooth disease\n* Major surgery within 4 weeks prior to the start or cycle 1 other than for diagnosis\n* Active autoimmune disease requiring therapy. Patients with autoimmune thyroid disease on a stable dose of thyroid replacement or type 1 diabetes on a stable dose of insulin are eligible.\n* Known or suspected history of HLH.",{"count":171,"type":20},41,[23],"The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma.\n\nThe names of the treatment interventions involved in this study are:\n\n* Glofitamab (T-cell bispecific antibody)\n* Polatuzumab (antibody-drug conjugate)\n* R-CHP (a chemotherapy regimen comprised of Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, and Prednisone)",[146,26],[146,176,177,178],"High-risk diffuse large B-cell Lymphoma","Chemotherapy","Immunotherapy","2026-03-03",{"date":181,"type":31},"2026-03-05",{"date":183,"type":31},"2023-04-06",{"date":185,"type":20},"2029-09-15",{"name":187,"class":162},"Jennifer Crombie, MD",3,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":208,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":212,"locationsCount":4},"100393251","nonconforming-lisocabtagene-maraleucel-expanded-access-protocol-100393251","NCT04400591","Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol","Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release","Inclusion Criteria:\n\n1. Subject and\u002For LAR must understand and voluntarily sign an informed consent form prior to any study-related assessments\u002Fprocedures being conducted.\n2. Subject was prescribed lisocabtagene maraleucel (liso-cel) for a diagnosis that is approved per local prescribing information, per treating physician assessment.\n3. Subject is ≥ 18 years of age at the time of signing the informed consent form.\n4. Subject had a subject-specific batch of liso-cel manufactured intended for commercial treatment; however, the final manufactured product did not meet the local commercial release criteria.\n5. Remanufacturing (eg, repeat leukapheresis and manufacturing) is deemed not feasible or clinically inappropriate per assessment of the treating physician in discussion with the subject.\n6. Subject is clinically stable, has recovered from any prior toxicities which places the subject at clinical risk prior to receiving LD chemotherapy, and has adequate bone marrow function to receive LD chemotherapy. The treating physician is advised to contact the Medical Monitor in the event there is any concern regarding administration of LD chemotherapy.\n7. Females of childbearing potential must:\n\n   1. Have a negative pregnancy test as verified by the treating physician within 7 days prior to the first dose of lymphodepleting chemotherapy following institutional testing methodology practices. This applies even if the subject practices true abstinence from heterosexual contact.\n   2. Either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, effective contraception without interruption. Contraception methods must include 1 highly effective method from screening until at least 12 months after the nonconforming liso-cel administration.\n   3. Agree to abstain from breastfeeding during study participation and for at least 12 months following nonconforming liso-cel administration.\n   4. There are insufficient exposure data to provide any recommendation concerning the duration of contraception and the abstaining from breastfeeding following treatment with liso-cel. Any decision regarding contraception and breastfeeding after infusion should be discussed with the treating physician.\n8. Male subjects must:\n\n   1. Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential for at least 12 months after nonconforming liso-cel administration even if the subject has undergone a successful vasectomy.\n   2. There are insufficient exposure data to provide any recommendation concerning the duration of contraception following treatment with liso-cel. Any decision regarding contraception after infusion should be discussed with the treating physician\n9. Subject must agree to not donate blood, organs, tissue, sperm or semen and egg cells for usage in other individuals for at least 1 year following nonconforming liso-cel administration.\n\nExclusion Criteria:\n\n1. Subject has a hypersensitivity to the active substance or to any of the excipients.\n2. Subject should not experience a significant worsening in clinical status that would, in the opinion of the treating physician, either increase the risk of adverse events associated with lymphodepleting chemotherapy, or exclude them from treatment with nonconforming liso-cel.\n3. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness, sociologic or geographic condition that would prevent the subject from participating in the Expanded Access Protocol complying with protocol requirements in the Investigator's judgement.\n4. Subject has any condition and\u002For laboratory abnormality that places the subject at unacceptable risk if he\u002Fshe were to participate in the Expanded Access Protocol based on the Investigator's judgement\n5. Pregnant or nursing women or has intention of becoming pregnant during the study.\n6. Subjects with primary central nervous system (CNS) lymphoma (note: subjects with secondary CNS involvement are allowed on study).\n7. Subject has uncontrolled hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection at the time of pretreatment evaluation\n8. Subject has uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of nonconforming liso-cel administration.\n9. Subject has active acute or chronic graft-versus-host disease (ie, GVHD)\n10. Subject should not be actively receiving anticancer treatment that would, in the opinion of the treating physician, either increase the risk of AEs associated with LD chemotherapy or CAR T therapy or interfere with site routine care treatment plan associated with CAR T therapy. The treating physician is advised to consult with the Medical Monitor for case discussion if needed.","EXPANDED_ACCESS","This is an expanded access protocol that will be conducted at sites qualified and approved to treat subjects with lisocabtagene maraleucel. Sometimes when lisocabtagene maraleucel is manufactured the drug does not pass all the testing results to be called lisocabtagene maraleucel. When this happens the drug is called nonconforming lisocabtagene maraleucel. The expanded access protocol will be used to allow subjects to receive nonconforming lisocabtagene maraleucel only if the potential benefit is better than the potential risk. This expanded access protocol is restricted to those subjects who were prescribed lisocabtagene maraleucel as part of their routine care.\n\nSubjects will first receive a lymphodepleting chemotherapy regimen and then be treated with nonconforming lisocabtagene maraleucel as the treatment plan.",[26],[200,201,202,203,204,205,206,207],"Expanded Access","JCAR017","Lisocabtagene Maraleucel","CAR T","nonconforming;","relapsed\u002Frefractory diffuse large B cell lymphoma","nonconforming lisocabtagene mareleucel","liso-cel","AVAILABLE","2025-12-04",{"date":211,"type":31},"2025-12-11",{"name":213,"class":38},"Juno Therapeutics, a Subsidiary of Celgene",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":221,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":21,"phases":224,"briefSummary":225,"conditions":226,"keywords":229,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":244},"100519619","phase-1-a-phase-iii-trial-of-aleta-001-for-the-treatment-of-participants-with-b-cell-malignancies-100519619","NCT06045910","A Phase I\u002FII Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies","A Cancer Research UK Phase I\u002FII Trial of ALETA-001 in Participants Who Have Received an Anti-CD19 CAR T-Cell Therapy for the Treatment of B-cell Malignancies","Inclusion Criteria:\n\nFor all participants\n\nCriteria to be met prior to enrolment in the trial:\n\n* Aged 16 years or over.\n* Written (signed and dated) informed consent and be capable of co-operating with ALETA-001 administration and follow-up.\n* Confirmed diagnosis of B-cell NHL according to World Health Organization (WHO) 2016 criteria.\n* Eastern Cooperative Oncology Group performance status of 0, 1 or 2.\n* Biochemical indices within protocol specified ranges.\n\nCohort Specific Inclusion criteria (for Phase I Cohorts A \\& B) Criteria to be met prior to enrolment in the trial.\n\n* Histologically confirmed diagnosis of relapsed\u002Frefractory LBCL or MCL.\n* Have received an approved anti-CD19 CAR T-cell therapy.\n* Objectively evaluable or measurable disease at 4 weeks (±1 week) post CAR T, which demonstrates:\n\n  * inadequate or incomplete response (PR or SD), or\n  * PD if there is a reasonable expectation of deriving benefit from trial treatment, or\n  * initial response followed by relapse within 9 months assessed according to Lugano Criteria.\n* Haematological indices within protocol specified ranges.\n\nCohort Specific Inclusion criteria (for Phase I Cohorts C \\& D) Criteria to be met prior to lymphodepleting chemotherapy for CAR T therapy.\n\n* Histologically confirmed diagnosis of relapsed\u002Frefractory LBCL or MCL.\n* Approved by the UK national CAR T Clinical Panel (NCCP) to receive an approved anti-CD19 CAR T-cell therapy.\n* Haematological indices within protocol specified ranges.\n* Adequate cardiac function within protocol specified ranges with no clinical symptoms or signs of heart failure.\n* Resting O2 saturation of ≥92% on room air.\n\nEligibility for participants in Phase II of the trial will depend on timing of administration of ALETA-001 which will be recommended by the Safety Review Committee (SRC).\n\nExclusion Criteria for all participants:\n\n* Active or previous malignancies of other types that, in the opinion of the Investigator, should exclude the participant. Exceptions include adequately treated cone biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin and patients with asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or who require only hormonal therapy and have had normal prostate specific antigen for \\>1 year prior to the start of therapy. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 2 years or more and are deemed at negligible risk for recurrence, are eligible for the trial.\n* Any ongoing toxic manifestation of previous anti-cancer treatment that, in the opinion of the Investigator, should exclude the participant.\n* Ongoing need for systemic immunosuppressive therapy other than replacement dose of corticosteroids. Intermittent topical, inhaled or intranasal corticosteroids are permitted.\n* Presence of active infections and\u002F or inflammatory disease requiring active management.\n* Documented current central nervous system involvement by lymphoma.\n* Women of childbearing potential (or are already pregnant or lactating) unless willing to adhere to protocol-defined contraceptive requirements.\n* Male patients with partners of childbearing potential unless willing to adhere to protocol-defined contraceptive requirements.\n* Major thoracic or abdominal surgery from which the participant has not yet recovered.\n* At high medical risk because of non-malignant systemic disease including active uncontrolled infection.\n* Hypersensitivity to any of the ingredients\u002Fexcipients in ALETA-001.\n* Participation in another interventional clinical trial, whilst taking part in this trial of ALETA-001. Participation in an observational trial or interventional clinical trial that does not involve administration of an IMP and that would not place an unacceptable burden on the participant, in the opinion of the Investigator and CDD, would be acceptable.\n* Participants with any congenital or acquired immunodeficiency syndrome or who are receiving immunosuppressive therapy (including any dose of systemic corticosteroids), or who are immunosuppressed post organ transplant. However, participants receiving inhaled corticosteroids and participants with a history of allergy (other than anaphylaxis) are eligible, as are participants with a history of autoimmune disease.\n* Any other condition that, in the Investigator's opinion, would mean that the trial is not in the best interests of the participant.\n* Concurrent radiotherapy (except for palliative reasons).\n\nCohort specific exclusion criteria prior to enrolment in the trial (for Phase I\n\nCohorts A \\& B):\n\n* Participants who have received any other systemic anti-cancer treatment post-CAR T.\n* Potential participants who experienced any of the following because of the initial CAR T treatment:\n\n  * Grade 4 CRS or ICANS post CAR T infusion.\n  * Grade ≥3 CRS or ICANS persisting beyond 7 days despite optimal therapy.\n  * Any Grade ≥1 CRS or ICANS must have fully resolved.\n* Any Grade ≥3 organ toxicity (other than haematologic toxicity) following CAR T infusion must have improved to Grade ≤2 for at least 48 hours prior to ALETA-001 infusion.\n\nCohort specific exclusion criteria prior to ALETA-001 infusion between Day 10-18 post CAR T-cell infusion (for Phase I Cohorts C \\& D):\n\n* Grade 4 CRS or ICANS post CAR T infusion.\n* Grade ≥3 CRS or ICANS persisting beyond 7 days despite optimal therapy.\n* Any Grade ≥2 CRS or ICANS must have improved to Grade ≤1 for at least 48 hours prior to ALETA-001 infusion.\n* ECOG performance status ≥3.\n* Any Grade ≥3 organ toxicity (other than haematologic toxicity) following CAR T infusion must have improved to Grade ≤2 for at least 48 hours prior to ALETA-001 infusion.\n* Any unresolved serious active infection which in the opinion of the Investigator precludes ALETA-001 infusion (ongoing need for IV antimicrobial therapy per se is not an exclusion).","16 Years",{"count":223,"type":20},84,[50,23],"This is a Phase I\u002FII multicentre, open-label trial designed to evaluate the efficacy, safety, tolerability, timing of administration and pharmacokinetics (PK) of a novel chimeric antigen receptor (CAR) T-cell engager, ALETA-001, administered by intravenous (IV) infusion as a single agent every 2 weeks in participants with B-cell malignancies post CD19 CAR T-cell therapy. This first in human study is divided into 2 parts: a safety lead-in phase (Phase I) and a dose expansion phase (Phase II). Different dose levels of ALETA-001 and timing of administration will be evaluated in Phase I in order to define a recommended dosing level and time of administration for Phase II. Phase II will further evaluate the safety, PK and therapeutic activity of ALETA-001.",[53,26,227,54,118,228],"Lymphoma, Mantle-Cell","Large B-cell Lymphoma",[230,231,232,233,234],"Neoplasms","Immunotherapy, Adoptive","Receptors, Chimeric Antigen","Receptors, Antigen, T-Cell","Antigens, CD19","2025-07-24",{"date":237,"type":31},"2025-07-28",{"date":239,"type":31},"2024-02-07",{"date":241,"type":20},"2029-12-21",{"name":243,"class":162},"Cancer Research UK",7,{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":252,"minAge":17,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":21,"phases":256,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":268,"leadSponsor":270,"locationsCount":4},"100560169","phase-3-a-phase-iii-clinical-trial-of-high-dose-rituximab-500mgm-combined-with-chop-regimen-in-the-treatment-of-male-patient-with-newly-diagnosed-advanced-dlbcl-100560169","NCT06573645","A Phase III Clinical Trial of High-dose Rituximab (500mg\u002Fm²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL","A Phase III Randomized Controlled Study Comparing High-dose Rituximab (500 mg\u002Fm²) Combined With CHOP Regimen Versus Standard-dose Rituximab (375 mg\u002Fm²) Combined With CHOP Regimen in Male Patients With Newly Diagnosed Advanced Diffuse Large B-cell Lymphoma","Key Inclusion Criteria:\n\n1. age \\\u003C75y, male patients\n2. According to the 2017 Revised WHO Classification criteria for lymphoma, the subject was diagnosed with DLBCL\n3. According to Ann Arbor staging, patients were classified as stage III-IV patients\n4. No previous anti-tumor systemic therapy or local radiation therapy for DLBCL\n5. Expected survival ≥6 months\n6. Have sufficient coagulation function and liver and kidney function\n7. Haver sufficient bone marrow function\n8. All patients should take medically approved contraceptive measures within 12 months after rituximab administration (specific circumstances should follow the listed drug label)\n9. Subjects were enrolled voluntarily, signed informed consent, and followed the experimental treatment protocol and visit plan\n\nKey Exclusion Criteria:\n\n1. Subjects assessed by the investigator to be intolerant to the R-CHOP regimen and\u002For any drug therapy;\n2. Any previous anti-lymphoma systemic therapy or local radiation therapy\n3. Consider patients with lymphoma involving the central nervous system (CNS) or diagnosed with primary CNS lymphoma (PCNSL); The diagnosis was primary mediastinal large B-cell lymphoma (PMBL)\n4. Previously received organ transplantation or hematopoietic stem cell transplantation\n5. Had received major surgery or major trauma within 4 weeks before the first medication (or before randomization), and had participated in clinical trials of non-anti-tumor drugs or medical devices within 4 weeks\n6. Have had malignant tumors other than the indications targeted in this study in the past three years\n7. Participants with any serious and\u002For uncontrolled systemic disease who are determined by the investigator to be unsuitable for participation in the study\n8. Major cardiovascular disease occurred within 6 months before the first medication (or before randomization)\n9. Any conditions that affect the patient's ingestion of the drug, as well as conditions that seriously affect the absorption or pharmacokinetic parameters of the drug in the trial, including difficult to control nausea and vomiting, short bowel syndrome, etc.\n10. Subjects who received live or attenuated vaccine within 4 weeks prior to initial administration (or prior to randomization) or planned to receive live vaccine during the study period or 4 weeks after the end of study treatment\n11. A hemorrhagic disease (such as von Willebrand disease or hemophilia A, hemophilia B, etc.) or according to the judgment of the investigator has a clear bleeding tendency\n12. have a serious peripheral nervous system or central nervous system disease.\n13. Warfarin or other vitamin K antagonists are required during the study\n14. There is an autoimmune disease that cannot be controlled or requires treatment within 4 weeks prior to the first dose (or prior to randomization)\n15. Doxorubicin has been used in the past ≥150 mg\u002Fm2\n16. The investigator believes that the subjects have other conditions that are not suitable for participation in this experiment.","MALE","75 Years",{"count":255,"type":20},428,[257],"PHASE3","Comparison of MODIFIED progression-free survival (Modified-PFS) in high-dose rituximab (500mg\u002Fm²) plus CHOP versus standard-dose rituximab plus CHOP in previously untreated (TN) stage III-IV male DLBCL patients",[26],[261,262,263],"lymphoma","Diffuse large B cell lymphoma","High doses rituximab","2024-08-23",{"date":266,"type":31},"2024-08-27",{"date":264,"type":20},{"date":269,"type":20},"2027-07-12",{"name":271,"class":162},"Xia Yi",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":21,"phases":281,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":163},"100538371","plasma-cfdna-testing-guiding-the-treatment-decisions-of-dlbcl-100538371","NCT06289959","Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL","A Prospective, Single-Center, Randomized, Controlled Study Guiding the Treatment of Diffuse Large B-Cell Lymphoma Patients Based on Plasma cfDNA Testing","Inclusion Criteria:\n\n* Age ≥ 18 years, gender not specified.\n* Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) confirmed by histopathological examination. Patients should test positive for plasma cfDNA before treatment (defined as positive for point mutations, CNV, IgH-related fusion, or IG clonal rearrangement) and achieve complete metabolic remission after 6 cycles of R-CHOP chemotherapy (evaluated by Lugano response assessment criteria).\n* Patients for whom the researcher predicts a life expectancy of \\>6 months.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Patients who have undergone autologous stem cell transplantation.\n* Patients with a history of other malignant tumors, except for basal cell carcinoma of the skin or in situ cervical cancer.\n* Patients with uncontrolled cardiovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, and other such conditions;\n* Primary central nervous system lymphoma.\n* Patients with mental illness or others known or suspected to be unable to fully comply with the study protocol.\n* Pregnant or lactating women.\n* HbsAg-positive patients who need to undergo HBV-DNA testing and can only be included if they seroconvert. Additionally, if the HbsAg test is negative but the HBcAb test is positive (regardless of HbsAb status), HBV-DNA testing is also required. If the result is positive, inclusion is possible only after seroconversion.\n* HIV-infected individuals.\n* Other concurrent and uncontrolled diseases that researchers believe may affect the medical condition of patients participating in the study.",{"count":280,"type":20},30,[282],"NA","A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and treatment practices for DLBCL patients.",[26],[286,287],"cfDNA","therapy","2024-03-01",{"date":290,"type":31},"2024-03-04",{"date":292,"type":20},"2024-02-25",{"date":294,"type":20},"2029-01-01",{"name":296,"class":162},"Second Affiliated Hospital of Soochow University"]